85 related articles for article (PubMed ID: 23199505)
1. Response guided therapy in patients with chronic hepatitis C - yesterday, today and tomorrow.
Ferenci P
Best Pract Res Clin Gastroenterol; 2012 Aug; 26(4):463-9. PubMed ID: 23199505
[TBL] [Abstract][Full Text] [Related]
2. Optimal treatment duration for patients with HCV genotype 1 infection.
Ferenci P
J Viral Hepat; 2012 Jan; 19 Suppl 1():7-13. PubMed ID: 22233408
[TBL] [Abstract][Full Text] [Related]
3. Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin.
Bonardi R; Tabone M; Manca A; Pellicano R; Ciancio A; Rizzetto M
Biomed Pharmacother; 2011 Jul; 65(4):303-6. PubMed ID: 21723079
[TBL] [Abstract][Full Text] [Related]
4. Sustained virological response based on the week 4 response in hepatitis C virus genotype 1 patients treated with peginterferons α-2a and α-2b, plus ribavirin.
Dogan UB; Akin MS; Yalaki S
Eur J Gastroenterol Hepatol; 2013 Nov; 25(11):1317-20. PubMed ID: 23680912
[TBL] [Abstract][Full Text] [Related]
5. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
[TBL] [Abstract][Full Text] [Related]
6. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
Hanouneh IA; Miller C; Aucejo F; Lopez R; Quinn MK; Zein NN
Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
[TBL] [Abstract][Full Text] [Related]
7. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.
Yu ML; Dai CY; Huang JF; Chiu CF; Yang YH; Hou NJ; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
Hepatology; 2008 Jun; 47(6):1884-93. PubMed ID: 18508296
[TBL] [Abstract][Full Text] [Related]
8. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection.
Fried MW; Hadziyannis SJ; Shiffman ML; Messinger D; Zeuzem S
J Hepatol; 2011 Jul; 55(1):69-75. PubMed ID: 21145856
[TBL] [Abstract][Full Text] [Related]
9. A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients.
Braun DL; Rauch A; Aouri M; Durisch N; Eberhard N; Anagnostopoulos A; Ledergerber B; Müllhaupt B; Metzner KJ; Decosterd L; Böni J; Weber R; Fehr J;
PLoS One; 2015; 10(7):e0133028. PubMed ID: 26176696
[TBL] [Abstract][Full Text] [Related]
10. Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.
Bernabucci V; Ciancio A; Petta S; Karampatou A; Turco L; Strona S; Critelli R; Todesca P; Cerami C; Sagnelli C; Rizzetto M; Cammà C; Villa E
World J Gastroenterol; 2014 Nov; 20(44):16726-33. PubMed ID: 25469044
[TBL] [Abstract][Full Text] [Related]
11. [Prediction of sustained viral response to combinational therapy with interferon and ribavirin in chronic hepatitis C by rapid viral response].
Li MH; Chen LJ; Qiu GH; Lu Y; Xie Y; Xu DZ
Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):497-500. PubMed ID: 19912682
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor.
Pearlman BL; Ehleben C
Hepatology; 2014 Jan; 59(1):71-7. PubMed ID: 23873583
[TBL] [Abstract][Full Text] [Related]
13. Boceprevir plus peginterferon α-2b/ribavirin in chronic hepatitis C genotype 1: impact of baseline viral load on sustained virologic response.
Gordon SC; Reddy KR; Jacobson IM; Poordad F; Bronowicki JP; Bacon B; Buti M; Hu KQ; Pedicone LD; Burroughs M; Brass CA; Albrecht JK; Lawitz EJ
J Clin Gastroenterol; 2014; 48(5):435-43. PubMed ID: 24177376
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
[TBL] [Abstract][Full Text] [Related]
15. Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy.
Sarrazin C; Shiffman ML; Hadziyannis SJ; Lin A; Colucci G; Ishida H; Zeuzem S
J Hepatol; 2010 Jun; 52(6):832-8. PubMed ID: 20385421
[TBL] [Abstract][Full Text] [Related]
16. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
Hézode C; Forestier N; Dusheiko G; Ferenci P; Pol S; Goeser T; Bronowicki JP; Bourlière M; Gharakhanian S; Bengtsson L; McNair L; George S; Kieffer T; Kwong A; Kauffman RS; Alam J; Pawlotsky JM; Zeuzem S;
N Engl J Med; 2009 Apr; 360(18):1839-50. PubMed ID: 19403903
[TBL] [Abstract][Full Text] [Related]
17. Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.
Manns MP; Markova AA; Calle Serrano B; Cornberg M
Liver Int; 2012 Feb; 32 Suppl 1():27-31. PubMed ID: 22212568
[TBL] [Abstract][Full Text] [Related]
18. Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response.
Ferenci P; Laferl H; Scherzer TM; Maieron A; Hofer H; Stauber R; Gschwantler M; Brunner H; Wenisch C; Bischof M; Strasser M; Datz C; Vogel W; Löschenberger K; Steindl-Munda P;
Gastroenterology; 2010 Feb; 138(2):503-12, 512.e1. PubMed ID: 19909752
[TBL] [Abstract][Full Text] [Related]
19. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients.
Khattab M; Eslam M; Sharwae MA; Shatat M; Ali A; Hamdy L
Am J Gastroenterol; 2010 Sep; 105(9):1970-7. PubMed ID: 20234345
[TBL] [Abstract][Full Text] [Related]
20. Plasma HCV-RNA decline in the first 48 h identifies hepatitis C virus mono-infected but not HCV/HIV-coinfected patients with an undetectable HCV viral load at week 4 of peginterferon-alfa-2a/ribavirin therapy.
Arends JE; Stuart JC; Baak LC; van der Ende ME; van Erpecum KJ; Simons CP; Boland GJ; van Baarle D; Hoepelman AI
J Viral Hepat; 2009 Dec; 16(12):867-75. PubMed ID: 19457139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
